Young David's Form 4 filing
Processa Pharmaceuticals, Inc. (PCSA) · filed Apr 13, 2023
- Accession no.
- 0000897069-23-000269
- Filed
- Apr 13, 2023, 4:51 PM ET
- Trade date
- Apr 11-13, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market purchases total $29.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Young DavidCIK 0001378166 | Director, Officer (President & CEO), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 11, 2023 | Common Stock | PPurchaseAcquired | +20,000 | $0.52F1 | +$10,400 | 370,424 | Direct | |
| Apr 12, 2023 | Common Stock | PPurchaseAcquired | +20,000 | $0.45 | +$9,000 | 390,424 | Direct | |
| Apr 13, 2023 | Common Stock | PPurchaseAcquired | +20,000 | $0.48F2 | +$9,600 | 410,424 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.49 to $0.53, inclusive. The Reporting Person undertakes to provide Processa Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
Referenced by the price of 1 transaction in Table I.
- F2
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.44 to $0.51, inclusive. The Reporting Person undertakes to provide Processa Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
Referenced by the price of 1 transaction in Table I.